Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Centessa to present on OX2R agonist discovery pipeline » 08:40
09/20/22
09/20
08:40
09/20/22
08:40
CNTA

Centessa

$4.66 /

+0.34 (+7.87%)

Centessa Pharmaceuticals…

Centessa Pharmaceuticals announced that non-clinical data from its oral orexin receptor 2 agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society meeting being held on September 27-30, 2022, in Athens, Greece. Centessa's OX2R agonists are designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1, with potential expansion into narcolepsy type 2, and other sleep disorders. The poster presentation will feature the non-clinical activity profiles of small-molecule OX2R agonists from multiple lead chemical series developed using structure-based drug design with an OX2R protein stabilized in the agonist conformation together with CryoEM and high-resolution protein crystallography. These novel OX2R agonist compounds showed high potency in activating recombinant human and endogenous mouse OX2Rs, with more than a thousand-fold selectivity for OX2R compared to OX1R. The OX2R agonists also showed efficacy in promoting wakefulness and in reducing cataplexy events in NT1 model mice, and increased wakefulness in healthy mice.

ShowHide Related Items >><<
CNTA Centessa
$4.66 /

+0.34 (+7.87%)

CNTA Centessa
$4.66 /

+0.34 (+7.87%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
CNTA Centessa
$4.66 /

+0.34 (+7.87%)

CNTA Centessa
$4.66 /

+0.34 (+7.87%)

CNTA Centessa
$4.66 /

+0.34 (+7.87%)

Hot Stocks
Centessa announces ODD granted to SerpinPC for treatment of hemophilia B » 09:08
09/14/22
09/14
09:08
09/14/22
09:08
CNTA

Centessa

$4.31 /

+0.205 (+5.00%)

Centessa Pharmaceuticals…

Centessa Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to SerpinPC, a novel inhibitor of activated protein C, APC, for the treatment of hemophilia B. Centessa plans to begin registrational studies of SerpinPC in the fourth quarter of 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins that is designed to allow more thrombin to be generated by inhibiting APC, thus rebalancing coagulation in hemophilia patients. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. "This designation from the FDA is an important milestone in the development of SerpinPC and underscores the need for new, innovative treatment options for patients with hemophilia B. We look forward to initiating registrational studies for SerpinPC later this year, as well as reporting the two-year follow-up data from the SerpinPC Phase 2a open label extension study in the fourth quarter."

ShowHide Related Items >><<
CNTA Centessa
$4.31 /

+0.205 (+5.00%)

CNTA Centessa
$4.31 /

+0.205 (+5.00%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
CNTA Centessa
$4.31 /

+0.205 (+5.00%)

CNTA Centessa
$4.31 /

+0.205 (+5.00%)

CNTA Centessa
$4.31 /

+0.205 (+5.00%)

Hot Stocks
Centessa announces NHPs PK, safety data for LB101 » 07:19
09/12/22
09/12
07:19
09/12/22
07:19
CNTA

Centessa

$4.08 /

+ (+0.00%)

Centessa Pharmaceuticals…

Centessa Pharmaceuticals announced non-clinical pharmacokinetic, PK, and safety data in non-human primates, NHPs, for LB101, its first LockBody candidate for solid tumors. Findings from these data reinforce the potential of its LockBody platform to minimize the systemic effects of potent immune effectors and significantly improve the therapeutic index. "These data, together with the non-clinical data presented at ASCO earlier this year, continue to validate our novel LockBody pharmacology, which leverages the natural cleaving of the human IgG-derived hinge to deliver powerful effectors like anti-CD47 into the tumor environment," said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. "Whereas current therapies targeting CD47 are encumbered with severe toxicities due to peripheral activity on circulating red blood cells, LB101 has the potential to optimally deliver anti-PD-L1 activity plus targeted anti-CD47 activity to the tumor micro-environment. These new non-clinical data demonstrate systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, resulting in the potential to achieve an enhanced therapeutic index, increased anti-tumor activity, and enable meaningful treatment for patients with solid tumors. We look forward to advancing LB101 into the clinic and plan to submit an IND late this year." In the study, male and female cynomolgus monkeys were administered LB101 intravenously, every 7 days over 28 days at doses of 5mg/kg, 20mg/kg, and 50mg/kg. The pharmacokinetics of LB101 were assessed and exhibited a typical IgG1-like PK profile. There were no adverse changes in hematologic parameters, no changes in body weights and no adverse toxicology findings.

ShowHide Related Items >><<
CNTA Centessa
$4.08 /

+ (+0.00%)

CNTA Centessa
$4.08 /

+ (+0.00%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
CNTA Centessa
$4.08 /

+ (+0.00%)

CNTA Centessa
$4.08 /

+ (+0.00%)

CNTA Centessa
$4.08 /

+ (+0.00%)

Over a month ago
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:34
08/12/22
08/12
09:34
08/12/22
09:34
CIEN

Ciena

$52.90 /

-1.08 (-2.00%)

, PRQR

ProQR Therapeutics

/

+

, CNTA

Centessa

$4.27 /

-0.43 (-9.15%)

, SIX

Six Flags

$21.12 /

-4.685 (-18.16%)

, OLO

Olo

$13.00 /

-0.235 (-1.78%)

, LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

, ELF

e.l.f. Beauty

$36.44 /

-0.02 (-0.05%)

, MSFT

Microsoft

$287.35 /

-1.82 (-0.63%)

, GDRX

GoodRx

$7.60 /

+0.205 (+2.77%)

, MREO

Mereo BioPharma

$1.15 /

-0.055 (-4.56%)

, BB

BlackBerry

$6.73 /

-0.185 (-2.68%)

, ADM

Archer Daniels

$84.14 /

+0.53 (+0.63%)

, LNT

Alliant Energy

$61.67 /

-0.295 (-0.48%)

, SNY

Sanofi

$43.46 /

-1.74 (-3.85%)

, SAFE

Safehold

$45.32 /

+1.88 (+4.33%)

Institutional investors…

ShowHide Related Items >><<
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

SIX Six Flags
$21.12 /

-4.685 (-18.16%)

SAFE Safehold
$45.32 /

+1.88 (+4.33%)

PRQR ProQR Therapeutics
/

+

OLO Olo
$13.00 /

-0.235 (-1.78%)

MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

MREO Mereo BioPharma
$1.15 /

-0.055 (-4.56%)

LNT Alliant Energy
$61.67 /

-0.295 (-0.48%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

GDRX GoodRx
$7.60 /

+0.205 (+2.77%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CIEN Ciena
$52.90 /

-1.08 (-2.00%)

BB BlackBerry
$6.73 /

-0.185 (-2.68%)

ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

CIEN Ciena
$52.90 /

-1.08 (-2.00%)

08/12/22 Morgan Stanley
Ciena upgraded to Overweight at Morgan Stanley as supply chain improves
08/12/22 Morgan Stanley
Ciena upgraded to Overweight from Equal Weight at Morgan Stanley
08/04/22 MKM Partners
Ciena assumed with a Buy at MKM Partners
07/14/22 JPMorgan
Ciena price target lowered to $62 from $72 at JPMorgan
PRQR ProQR Therapeutics
/

+

08/12/22 Chardan
ProQR Therapeutics downgraded to Neutral from Buy at Chardan
08/11/22 Raymond James
ProQR upgraded to Outperform at Raymond James on RNA editing 'conviction'
08/11/22 Raymond James
ProQR Therapeutics upgraded to Outperform from Market Perform at Raymond James
05/12/22 Cantor Fitzgerald
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
CNTA Centessa
$4.27 /

-0.43 (-9.15%)

08/12/22 Morgan Stanley
Centessa double downgraded to Underweight from Overweight at Morgan Stanley
08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
SIX Six Flags
$21.12 /

-4.685 (-18.16%)

08/12/22 Deutsche Bank
Six Flags price target lowered to $38 from $56 at Deutsche Bank
08/12/22 Truist
Six Flags price target lowered to $20 from $32 at Truist
08/12/22 Stifel
Six Flags price target lowered to $28 from $35 at Stifel
08/12/22 KeyBanc
Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2
OLO Olo
$13.00 /

-0.235 (-1.78%)

08/12/22 RBC Capital
Olo price target lowered to $12 from $17 at RBC Capital
08/12/22 Truist
Olo price target lowered to $16 from $25 at Truist
08/12/22 Piper Sandler
Olo downgraded to Neutral from Overweight at Piper Sandler
08/12/22 Stifel
Olo downgraded to Hold from Buy at Stifel
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

08/12/22 Canaccord
CS Disco downgraded to Hold at Canaccord as estimates get reset
08/12/22 Stifel
CS Disco price target lowered to $30 from $40 at Stifel
08/12/22 BofA
CS Disco downgraded to Neutral from Buy at BofA
08/12/22 Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform at Cowen on valuation
08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform from Outperform at Cowen
08/04/22 Truist
e.l.f. Beauty price target raised to $40 from $35 at Truist
07/21/22 JPMorgan
e.l.f. Beauty price target raised to $35 from $30 at JPMorgan
MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

08/11/22 Guggenheim
Microsoft initiated with a Neutral at Guggenheim
08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
08/04/22 MKM Partners
8x8 initiated with a Neutral at MKM Partners
08/04/22 Deutsche Bank
Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank
GDRX GoodRx
$7.60 /

+0.205 (+2.77%)

08/11/22 DA Davidson
GoodRx initiated with a Neutral at DA Davidson
08/09/22 Goldman Sachs
Goldman Sachs raises GoodRx price target to $10 amid grocer issue resolution
08/09/22 RBC Capital
GoodRx price target raised to $11 from $6.50 at RBC Capital
08/09/22 Barclays
GoodRx price target raised to $13 from $12 at Barclays
MREO Mereo BioPharma
$1.15 /

-0.055 (-4.56%)

08/12/22 Cantor Fitzgerald
Mereo BioPharma initiated with an Overweight at Cantor Fitzgerald
06/06/22 Needham
Mereo BioPharma price target lowered to $5 from $10 at Needham
BB BlackBerry
$6.73 /

-0.185 (-2.68%)

08/12/22 Baird
BlackBerry initiated with a Neutral at Baird
06/24/22 TD Securities
TD Securities cuts BlackBerry target to $5 after 'low-quality' beat
05/19/22 Canaccord
BlackBerry price target lowered to $6 from $7 at Canaccord
04/01/22 Canaccord
BlackBerry results in-line but guidance disappoints, says Canaccord
ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

08/12/22 Wolfe Research
Wolfe Research starts Archer Daniels at Outperform on 'competitive' dividend
08/11/22 Wolfe Research
Archer Daniels initiated with an Outperform at Wolfe Research
07/27/22 Baird
Archer Daniels price target raised to $94 from $87 at Baird
06/30/22 BofA
Bunge upgraded to Buy from Neutral at BofA
LNT Alliant Energy
$61.67 /

-0.295 (-0.48%)

08/12/22 BofA
BofA upgrades 'IRA winner' Alliant Energy to Buy
08/12/22 BofA
Alliant Energy upgraded to Buy from Neutral at BofA
08/08/22 BofA
Alliant Energy price target raised to $62 from $57 at BofA
07/18/22 Barclays
Alliant Energy price target lowered to $62 from $68 at Barclays
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

08/12/22 Deutsche Bank
Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone
08/12/22 JPMorgan
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
SAFE Safehold
$45.32 /

+1.88 (+4.33%)

08/12/22 Mizuho
Safehold upgraded to Buy from Neutral at Mizuho
08/11/22 Truist
iStar tax-free combination to internalize Safehold management team, says Truist
07/15/22 Morgan Stanley
Safehold price target lowered to $85 from $100 at Morgan Stanley
06/28/22 B. Riley
B. Riley says buy iStar into expected merger with Safehold
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

SIX Six Flags
$21.12 /

-4.685 (-18.16%)

SAFE Safehold
$45.32 /

+1.88 (+4.33%)

PRQR ProQR Therapeutics
/

+

OLO Olo
$13.00 /

-0.235 (-1.78%)

MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

LNT Alliant Energy
$61.67 /

-0.295 (-0.48%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

GDRX GoodRx
$7.60 /

+0.205 (+2.77%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CIEN Ciena
$52.90 /

-1.08 (-2.00%)

BB BlackBerry
$6.73 /

-0.185 (-2.68%)

ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

  • 03
    Mar
  • 23
    Sep
  • 15
    Sep
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

MREO Mereo BioPharma
$1.15 /

-0.055 (-4.56%)

ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

SIX Six Flags
$21.12 /

-4.685 (-18.16%)

OLO Olo
$13.00 /

-0.235 (-1.78%)

MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

GDRX GoodRx
$7.60 /

+0.205 (+2.77%)

ELF e.l.f. Beauty
$36.44 /

-0.02 (-0.05%)

CIEN Ciena
$52.90 /

-1.08 (-2.00%)

BB BlackBerry
$6.73 /

-0.185 (-2.68%)

ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

MSFT Microsoft
$287.35 /

-1.82 (-0.63%)

GDRX GoodRx
$7.60 /

+0.205 (+2.77%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

BB BlackBerry
$6.73 /

-0.185 (-2.68%)

ADM Archer Daniels
$84.14 /

+0.53 (+0.63%)

Downgrade
Centessa double downgraded to Underweight from Overweight at Morgan Stanley » 05:36
08/12/22
08/12
05:36
08/12/22
05:36
CNTA

Centessa

$4.27 /

-0.43 (-9.15%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison double downgraded Centessa to Underweight from Overweight with a price target of $5, down from $10. Harrison tells investors in a research note that he was "clearly wrong" on his assessment of Centessa's pipeline, with three of the late stage assets being discontinued following the failure of lixivaptan. While management has enough cash and early stage assets to potentially drive long-term value, Harrison is moving to Underweight to reflect the lack of near-term upside for Centessa and the need to wait for other early stage pipeline programs to mature before they can contribute meaningful value.

ShowHide Related Items >><<
CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

08/12/22 Morgan Stanley
Centessa downgraded to Underweight from Overweight at Morgan Stanley
08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

Downgrade
Centessa downgraded to Underweight from Overweight at Morgan Stanley » 05:29
08/12/22
08/12
05:29
08/12/22
05:29
CNTA

Centessa

$4.27 /

-0.43 (-9.15%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison downgraded Centessa to Underweight from Overweight with a price target of $5, down from $10.

ShowHide Related Items >><<
CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

08/11/22 BMO Capital
Centessa price target lowered to $11 from $19 at BMO Capital
06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
02/11/22 Goldman Sachs
Centessa assumed with a Neutral at Goldman Sachs
CNTA Centessa
$4.27 /

-0.43 (-9.15%)

CNTA Centessa
$4.27 /

-0.43 (-9.15%)

Recommendations
Centessa price target lowered to $11 from $19 at BMO Capital » 07:03
08/11/22
08/11
07:03
08/11/22
07:03
CNTA

Centessa

$4.74 /

-0.49 (-9.37%)

BMO Capital analyst…

BMO Capital analyst Kostas Biliouris lowered the firm's price target on Centessa to $11 from $19 but keeps an Outperform rating on the shares. The analyst is adjusting his model following the company's announcement yesterday that it is discontinuing development of ZF874 following a recent report of an adverse event. Biliouris adds however that Centessa's hemophilia program remains intact, and he believes that the management team can successfully develop SerpinPC further, maintaining his assumed SerpinPC probability of success at 30%.

ShowHide Related Items >><<
CNTA Centessa
$4.74 /

-0.49 (-9.37%)

CNTA Centessa
$4.74 /

-0.49 (-9.37%)

06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
02/11/22 Goldman Sachs
Centessa assumed with a Neutral at Goldman Sachs
CNTA Centessa
$4.74 /

-0.49 (-9.37%)

CNTA Centessa
$4.74 /

-0.49 (-9.37%)

Earnings
Centessa reports Q2 EPS (69c) vs. (65c) a year ago » 06:37
08/10/22
08/10
06:37
08/10/22
06:37
CNTA

Centessa

$5.02 /

+ (+0.00%)

Cash and Cash…

Cash and Cash Equivalents: $484.2M as of June 30, which the company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.

ShowHide Related Items >><<
CNTA Centessa
$5.02 /

+ (+0.00%)

CNTA Centessa
$5.02 /

+ (+0.00%)

06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
02/11/22 Goldman Sachs
Centessa assumed with a Neutral at Goldman Sachs
CNTA Centessa
$5.02 /

+ (+0.00%)

CNTA Centessa
$5.02 /

+ (+0.00%)

Hot Stocks
Centessa to discontinue development of ZF874 » 06:36
08/10/22
08/10
06:36
08/10/22
06:36
CNTA

Centessa

$5.02 /

+ (+0.00%)

The company announced…

The company announced its decision to discontinue development of ZF874 following a recent report of an adverse event involving elevated liver enzymes in a PiMZ subject dosed with 5 mg/kg BID of ZF874 in the Phase 1 study. ZF874, a pharmacological chaperone designed to rescue the folding of the Z variant of alpha-1-antitrypsin, was in a Phase 1 study for the treatment of AATD. As previously reported in November 2021, elevated liver enzymes were observed in a subject dosed with 15 mg/kg BID of ZF874 in the first cohort of patients within Part B of the Phase 1 study. Based on the results observed to date, the company concluded that ZF874 was unlikely to achieve the desired target product profile. Dr. Saha concluded, "While this is disappointing news for the A1AT patient community, we continue to believe that the pharmacological chaperone approach has the potential to address both the lung and liver manifestations of AATD. We are analyzing data from the Phase 1 study to help inform potential future development plans for our back-up compounds."

ShowHide Related Items >><<
CNTA Centessa
$5.02 /

+ (+0.00%)

CNTA Centessa
$5.02 /

+ (+0.00%)

06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
02/11/22 Goldman Sachs
Centessa assumed with a Neutral at Goldman Sachs
CNTA Centessa
$5.02 /

+ (+0.00%)

CNTA Centessa
$5.02 /

+ (+0.00%)

Hot Stocks
Centessa appoints Rotmas as SVP, Regulatory Affairs » 08:09
07/25/22
07/25
08:09
07/25/22
08:09
CNTA

Centessa

$4.54 /

-0.655 (-12.61%)

Centessa Pharmaceuticals…

Centessa Pharmaceuticals announced the appointment of Harris Rotman, PhD, as Senior Vice President, SVP, Regulatory Affairs. Prior to joining Centessa, Dr. Rotman served as Senior Vice President, Head of Regulatory Affairs at SwanBio Therapeutics, where he was responsible for managing the company's neuromuscular disease gene therapy programs.

ShowHide Related Items >><<
CNTA Centessa
$4.54 /

-0.655 (-12.61%)

CNTA Centessa
$4.54 /

-0.655 (-12.61%)

06/16/22 BMO Capital
Centessa initiated with an Outperform at BMO Capital
06/03/22 Jefferies
Centessa downgraded to Hold from Buy at Jefferies
02/11/22 Goldman Sachs
Centessa assumed with a Neutral at Goldman Sachs
CNTA Centessa
$4.54 /

-0.655 (-12.61%)

CNTA Centessa
$4.54 /

-0.655 (-12.61%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.